Beta

Atyr pharma, inc.ATYR.US Overview

US StockHealthcare
(No presentation for ATYR)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ATYR AI Insights

ATYR Overall Performance

ATYR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ATYR Recent Performance

0.38%

Atyr pharma, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ATYR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ATYR's Trend

ATYR Key Information

ATYR Valuation Metrics

ATYR Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Price of ATYR

ATYR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ATYR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
405.16
PB Ratio
1.15
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-39009.47%
Revenue Growth (YoY)
-19.15%
Profit Growth (YoY)
-19.15%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
405.16
PB Ratio
1.15
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-39009.47%
Revenue Growth (YoY)
-19.15%
Profit Growth (YoY)
-19.15%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ATYR's latest earnings report released?

    The most recent financial report for Atyr pharma, inc. (ATYR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATYR's short-term business performance and financial health. For the latest updates on ATYR's earnings releases, visit this page regularly.

  • How much debt does ATYR have?

    As of the end of the reporting period, Atyr pharma, inc. (ATYR) had total debt of 12.03M, with a debt ratio of 0.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ATYR have?

    At the end of the period, Atyr pharma, inc. (ATYR) held Total Cash and Cash Equivalents of 12.98M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ATYR's EPS continuing to grow?

    According to the past four quarterly reports, Atyr pharma, inc. (ATYR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ATYR?

    Atyr pharma, inc. (ATYR)'s Free Cash Flow (FCF) for the period is -12.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ATYR?

    The latest valuation data shows Atyr pharma, inc. (ATYR) has a Price-To-Earnings (PE) ratio of -1.19 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.